New Competition with Ipsen

Discussion in 'Novartis' started by Anonymous, Oct 20, 2014 at 1:40 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Ipsen doing interviews for new Oncology division and I've been called to do one. Not sure about it. It appears that Novartis' Sandostatin LAR will be competition. What is this market Like? How is Novartis preparing you for this change? You guys think it will make an impact? I definitely don't want to take something that is going to completely suck.
     

  2. Anonymous

    Anonymous Guest

    Ipsen is a complete failure. Senior Management is incompetent. And the icing on the cake is that it is a French company.
     
  3. Anonymous

    Anonymous Guest

    You may want to check out the Novartis pipeline , a new drug to compete should get approval soon (signifor lar)
     
  4. Anonymous

    Anonymous Guest

    Better French than Swiss. We can't keep getting away with off label sandostatin sales. The MSLs can't keep acting like reps and keep promoting promid. Someone's gonna blow that whistle sooner or later
     
  5. Anonymous

    Anonymous Guest

    The new woman in charge at Ipsen is an incompetent, unethical moron.
     
  6. Anonymous

    Anonymous Guest

    They hired Joe Adduci as one of the 4-5 US District Managers in Oncology there. Enough said. A total incomp. in ONC
     
  7. Anonymous

    Anonymous Guest


    Are they serious. That dude is a Pharma Regional Director, not a field manager. Is so removed both of field activity & ONC.
     
  8. Anonymous

    Anonymous Guest

    Beats selling Affinitor - #nobonus